{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05231785",
            "orgStudyIdInfo": {
                "id": "ALN-APP-001"
            },
            "secondaryIdInfos": [
                {
                    "id": "2023-508363-79-00",
                    "type": "OTHER",
                    "domain": "EU CT Number"
                }
            ],
            "organization": {
                "fullName": "Alnylam Pharmaceuticals",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD",
            "officialTitle": "A Randomized, Double-blind, Placebo-controlled Single Ascending Dose and Open-label Multi-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ALN-APP in Adult Patients With Early-onset Alzheimer's Disease (EOAD)",
            "therapeuticArea": [
                "Neurology"
            ],
            "study": "a-study-to-evaluate-the-safety-and-tolerability-of-aln-app-in-patients-with-eoad"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-02-04",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-07-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-07-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-01-30",
            "studyFirstSubmitQcDate": "2022-01-30",
            "studyFirstPostDateStruct": {
                "date": "2022-02-09",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-18",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-19",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Alnylam Pharmaceuticals",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of a single dose and multiple doses of ALN-APP administered by intrathecal (IT) injection in adult patients with early-onset Alzheimer's Disease (EOAD). Maximum treatment duration for Part A: single dose. Maximum treatment duration for Part B: 12 months."
        },
        "conditionsModule": {
            "conditions": [
                "Early-Onset Alzheimer Disease"
            ],
            "keywords": [
                "EOAD"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "TRIPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 60,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Part A: ALN-APP",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will be administered a single dose of ALN-APP.",
                    "interventionNames": [
                        "Drug: ALN-APP"
                    ]
                },
                {
                    "label": "Part A: Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Participants will be administered a single dose of placebo.",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                },
                {
                    "label": "Part B:",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will be administered multiple doses of ALN-APP.",
                    "interventionNames": [
                        "Drug: ALN-APP"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "ALN-APP",
                    "description": "ALN-APP will be administered intrathecally (IT)",
                    "armGroupLabels": [
                        "Part A: ALN-APP",
                        "Part B:"
                    ],
                    "otherNames": [
                        "mivelsiran"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Placebo will be administered IT",
                    "armGroupLabels": [
                        "Part A: Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Part A: Frequency of Adverse Events",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "Part B: Frequency of Adverse Events",
                    "timeFrame": "Up to 24 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Part A and Part B: Change from Baseline in Levels of Cerebrospinal Fluid (CSF) Soluble Amyloid Precursor Protein Alpha (sAPP\u03b1) and Soluble Amyloid Precursor Protein Beta (sAPP\u03b2)",
                    "timeFrame": "Part A up to 12 months; Part B up to 24 months"
                },
                {
                    "measure": "Part A and Part B: Area Under the Plasma Concentration-time Curve (AUC) of ALN-APP and of Potential Metabolites",
                    "timeFrame": "Part A up to 12 months; Part B up to 24 months"
                },
                {
                    "measure": "Part A and Part B: Maximum Observed Plasma Concentration (Cmax) of ALN-APP and of Potential Metabolites",
                    "timeFrame": "Part A up to 12 months; Part B up to 24 months"
                },
                {
                    "measure": "Part A: Fraction of ALN-APP and Potential Metabolites Excreted in the Urine (fe)",
                    "timeFrame": "Up to 1 day"
                },
                {
                    "measure": "Part A and Part B: Concentration of ALN-APP and Potential Metabolites at Time 't' (Ct) in Plasma and CSF",
                    "timeFrame": "Part A up to 12 months; Part B up to 24 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Has mild cognitive impairment or mild dementia due to EOAD\n* Has Clinical Dementia Rating (CDR) global score 0.5 or 1.0 and Mini Mental State Examination (MMSE) \\>20\n\nExclusion Criteria:\n\n* Has Non-Alzheimer's disease dementia\n* Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>2\u00d7upper limit of normal (ULN)\n* Has estimated glomerular filtration rate (eGFR) \\<45 mL/min/1.73m\\^2 at Screening\n* Has recently received an investigational agent\n* Has recent treatment with amyloid-targeting antibody\n\nNote: other protocol defined inclusion / exclusion criteria apply",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Alnylam Clinical Trial Information Line",
                    "role": "CONTACT",
                    "phone": "1-877-ALNYLAM",
                    "email": "clinicaltrials@alnylam.com"
                },
                {
                    "name": "Alnylam Clinical Trial Information Line",
                    "role": "CONTACT",
                    "phone": "1-877-256-9526",
                    "email": "clinicaltrials@alnylam.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Medical Director",
                    "affiliation": "Alnylam Pharmaceuticals",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Clinical Trial Site",
                    "status": "RECRUITING",
                    "city": "San Diego",
                    "state": "California",
                    "zip": "92103",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.71533,
                        "lon": -117.15726
                    }
                },
                {
                    "facility": "Clinical Trial Site",
                    "status": "RECRUITING",
                    "city": "Indianapolis",
                    "state": "Indiana",
                    "zip": "46202",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.76838,
                        "lon": -86.15804
                    }
                },
                {
                    "facility": "Clinical Trial Site",
                    "status": "RECRUITING",
                    "city": "Toronto",
                    "state": "Ontario",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 43.70011,
                        "lon": -79.4163
                    }
                },
                {
                    "facility": "Clinical Trial Site",
                    "status": "RECRUITING",
                    "city": "Montr\u00e9al",
                    "state": "Quebec",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 45.50884,
                        "lon": -73.58781
                    }
                },
                {
                    "facility": "Clinical Trial Site",
                    "status": "RECRUITING",
                    "city": "Amsterdam",
                    "country": "Netherlands",
                    "geoPoint": {
                        "lat": 52.37403,
                        "lon": 4.88969
                    }
                },
                {
                    "facility": "Clinical Trial Site",
                    "status": "RECRUITING",
                    "city": "London",
                    "country": "United Kingdom",
                    "geoPoint": {
                        "lat": 51.50853,
                        "lon": -0.12574
                    }
                },
                {
                    "facility": "Clinical Trial Site",
                    "status": "RECRUITING",
                    "city": "Sheffield",
                    "country": "United Kingdom",
                    "geoPoint": {
                        "lat": 53.38297,
                        "lon": -1.4659
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000544",
                    "term": "Alzheimer Disease"
                }
            ],
            "ancestors": [
                {
                    "id": "D000003704",
                    "term": "Dementia"
                },
                {
                    "id": "D000001927",
                    "term": "Brain Diseases"
                },
                {
                    "id": "D000002493",
                    "term": "Central Nervous System Diseases"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                },
                {
                    "id": "D000024801",
                    "term": "Tauopathies"
                },
                {
                    "id": "D000019636",
                    "term": "Neurodegenerative Diseases"
                },
                {
                    "id": "D000019965",
                    "term": "Neurocognitive Disorders"
                },
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3885",
                    "name": "Alzheimer Disease",
                    "asFound": "Early Onset Alzheimer's Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6904",
                    "name": "Dementia",
                    "relevance": "LOW"
                },
                {
                    "id": "M5204",
                    "name": "Brain Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5742",
                    "name": "Central Nervous System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M23002",
                    "name": "Tauopathies",
                    "relevance": "LOW"
                },
                {
                    "id": "M21558",
                    "name": "Neurodegenerative Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M21836",
                    "name": "Neurocognitive Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "T2192",
                    "name": "Familial Alzheimer Disease",
                    "asFound": "Alzheimer's Disease",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}